Abstract: The present invention provides compounds and methods for treating MKP-5 modulated disease. In certain embodiments, the MKP-5 modulated disease is a fibrotic disease.

Abstract: In one aspect, the present disclosure describes tetrahydropyridine compounds of formula (I), which are 5-HT2A receptor agonists that exhibit selective binding to the 5-HT2A receptor over the 5-HT2B receptor. In certain embodiments, the compound of formula (I) is a compound of formula (II). Also provided herein are methods of treating, ameliorating, and/or preventing neurological diseases and disorders with compounds of formula (II).

Abstract: The present-disclosure relates to the discovery of novel 2-amino-dihydropteridinone compounds and analogues thereof, which are capable of inhibiting phosphatidylinositol phosphate kinases. In certain embodiments, the compounds of the present disclosure can be used to treat p53-null cancer in a subject. In other embodiments, the compounds of the present disclosure can be used to treat metabolic disorders in a subject, including but not limited to type 2 diabetes and/or obesity.

Abstract: The present invention provides compounds and methods for treating MKP-5 modulated disease. In certain embodiments, the MKP-5 modulated disease is a fibrotic disease.

Abstract: The present invention provides compounds and methods for treating, ameliorating, and/or preventing a MKP-5 modulated disease. In certain embodiments, the MKP-5 modulated disease is a fibrotic disease.

Abstract: Provided herein are thiostrepton analogues, such as but not limited to compounds of Formula I, with improved aqueous solubility and antibacterial properties against antibiotic-resistant bacterial strains. The methods of the disclosure further provide a chemoselective way to introduce diverse functionality into peptides or protein comprising a dehydroalanine residue.

Abstract: The present-disclosure relates to the discovery of novel 2-amino-dihydropteridinone compounds and analogues thereof, which are capable of inhibiting phosphatidylinositol phosphate kinases. In certain embodiments, the compounds of the present disclosure can be used to treat p53-null cancer in a subject. In other embodiments, the compounds of the present disclosure can be used to treat metabolic disorders in a subject, including but not limited to type 2 diabetes and/or obesity.

Abstract: The present invention provides compounds and methods for treating, ameliorating, and/or preventing a MKP-5 modulated disease. In certain embodiments, the MKP-5 modulated disease is a fibrotic disease.

Abstract: Systems and method are provided for forming an integrated communication network. The network includes a plurality of locally distributed integrated communications modules (ICMs) which are placed at predetermined positions. The ICMs monitor a plurality of roaming communication devices that communicate using both the cellular communication network and the internet. Further, the integrated communication network forms a private database on the roaming sender communication device to allow data communication with a specifically identified roaming communication device.

Abstract: Systems and method are provided for forming an integrated communication network. The network includes a plurality of locally distributed integrated communications modules (ICMs) which are placed at predetermined positions. The ICMs monitor a plurality of roaming communication devices that communicate using both the cellular communication network and the internet. Further, the integrated communication network forms a private data base on the roaming sender communication device to allow data communication with a specifically identified roaming communication device.